+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021

  • ID: 5359607
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 37 pages
  • Global Markets Direct

FEATURED COMPANIES

  • CombiGene AB
  • Gila Therapeutics Inc
  • XL-protein GmbH
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • CombiGene AB
  • Gila Therapeutics Inc
  • XL-protein GmbH
  • MORE
Introduction
  • Report Coverage
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
  • CombiGene AB
  • Gila Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • XL-protein GmbH
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles

CG-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
GT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
GT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PYY-1119 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
XL-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones

Featured News & Press Releases
  • Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc
  • Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
  • Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
  • Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
  • Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
  • Dec 14, 2020: With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
  • Oct 30, 2020: CombiGene comments the final preclinical steps
  • Oct 01, 2020: CombiGene one step closer to clinical trials
  • Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies
  • Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
  • Sep 11, 2020: CombiGene’s new agreement important for future clinical studies
  • Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
  • Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
  • Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
  • Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by CombiGene AB, 2021
  • Pipeline by Gila Therapeutics Inc, 2021
  • Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Pipeline by XL-protein GmbH, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • CombiGene AB
  • Gila Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • XL-protein GmbH
Note: Product cover images may vary from those shown
Adroll
adroll